-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.
-
Summary
-
Apellis Pharmaceuticals, Inc. quarterly Deferred Tax Assets, Operating Loss Carryforwards history and change rate from Q4 2016 to Q4 2024.
- Apellis Pharmaceuticals, Inc. Deferred Tax Assets, Operating Loss Carryforwards for the quarter ending 31 Dec 2024 was $312,672,000, a 5% decline year-over-year.
Deferred Tax Assets, Operating Loss Carryforwards, Quarterly (USD)
Deferred Tax Assets, Operating Loss Carryforwards, YoY Quarterly Change (%)